



Science Report 2011

Profil Institut für Stoffwechselforschung GmbH

Hellersbergstrasse 9

41460 Neuss

www.profil.com

Summary

Cumulative Impact Factor	
Profil Author first/last Position	ΣIF_{2010} : 32,169
Profil Author first/last Position and Study performed in Neuss	ΣIF_{2010} : 19,683
Profil Author first/last Position and Study performed in Neuss or Review	ΣIF_{2010} : 24,406
Scientific Publications	
Original Articles	22 (ΣIF_{2010} : 69,672)
Reviews	8 (ΣIF_{2010} : 4,723)
Letters and Comments	3 (ΣIF_{2010} : 6,973)
Cumulative Impact Factor	81,368
Book Chapters	2
Scientific Congress Presentations	
Oral Presentations	19
Poster Presentations	21
Advanced Training Courses	
Science Sessions	11
Trainings with External Participants	3
Scientific Communication	
Newspaper articles	3
Granted Research Projects	5
Awards & Appointments	1

Scientific Publications

Original Articles

1. Jax T, Heise T, Nosek L, Gable J, Lim G, Calentine C Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy. **J Diabetes Sci Technol** 5:345-352, 2011 IF₂₀₁₀: -
2. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. **Diabetes Care** 34:669-74, 2011 IF₂₀₁₀: 6,718
3. Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H, DIATOR Study Group Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the randomized DIATOR Trial. **PLoS One** 6:e17554, 2011 IF₂₀₁₀: 4,411
4. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. **Diabetes Obes Metab** 13:939-946, 2011 IF₂₀₁₀: 3,415
5. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S U-100, pH-neutral formulation of VIAject[®]: faster onset of action than insulin lispro in patients with type 1 diabetes. **Diabetes Obes Metab** DOI:10.1111/j.1463-1326.2011.01516.x, 2011 IF₂₀₁₀: 3,415
6. Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. **J Clin Pharmacol** 51(6):951-5, 2011 IF₂₀₁₀: 3,590
7. Flint A, Kapitza C, Hindsberger C, Zdravkovic M The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. **Adv Ther** 28(3): 213-26, 2011 IF₂₀₁₀: 1,668
8. Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. **Diabetes Technol Ther** 13(4):443-50, 2011 IF₂₀₁₀: 2,146
9. Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. **Diabetes Technol Ther** 13(4):435-42, 2011 IF₂₀₁₀: 2,146
10. Dobbins RL, O'Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, Tao W, Hussey EK Remogliflozin Etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus patients. **Diabetes Obes Metab** 14(1):15-22, 2012 IF₂₀₁₀: 3,415
11. Kapitza C, Zdravkovic M, Hindsberger C, Flint A The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. **Adv Ther** 28(8): 650-60, 2011 IF₂₀₁₀: 1,668

12. Smith SM, Heer M, Wang Z, Huntoon CL, Zwart SR Long-Duration Space Flight and Bed Rest Effects on Testosterone and Other Steroids. **J Clin Endocrinol Metab**, Nov 2 Epub ahead of print, 2011 IF₂₀₁₀: 6,495
13. Baecker N, Frings-Meuthen P, Heer M, Mester J, Liphardt AM Effects of vibration training on bone metabolism: results from a short-term bed rest study. **Eur J Appl Physiol**, Sep 6 Epub ahead of print, 2011 IF₂₀₁₀: 2,214
14. Frings-Meuthen P, Buehlmeier J, Baecker N, Stehle P, Fimmers R, May F, Kluge G, Heer M High sodium chloride intake exacerbates immobilization-induced bone resorption and protein losses. **J Appl Physiol**, 111(2):537-42, 2011 IF₂₀₁₀: 4,232
15. Plum L, Ahmed L, Febres G, Bessler M, Inabnet W, Kunreuther E, McMahon DJ, Korner J Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. **Obesity** 19: 2149-2157, 2011 IF₂₀₁₀: 3,531
16. Kruczek C, Keitel V, Bidmon HJ, Schliess F, Häussinger D Ammonia increases nitric oxide, free Zn(2+) and metallothionein mRNA expression in cultured rat astrocytes. **Biol Chem** 392(12):1155-65, 2011 IF₂₀₁₀: 3,603
17. Doerr R, Hoffmann U, Otter W, Heinemann L, Hunger-Battefeld W, Kulzer B, Klinge A, Lodwig V, Moritz A, Amann-Zalan I, Sturm D, Tschoepe D, Spitzer SG, Stumpf J, Lohmann T, Schnell O Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography: the Silent Diabetes study. **Diabetologia** 54:2923-2930, 2011 IF₂₀₁₀:6,973
18. Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Steiner S Reduction of postprandial glycemic excursions in patients with type 1 diabetes: A novel human insulin formulation vs. a rapid-acting insulin analog and regular human insulin. **J Diabetes Sci Technol** 5:681-686, 2011 IF₂₀₁₀: -
19. Caduff A, Heinemann L, Talary M, di Benedetto G, Theander S Dynamics of blood electrolytes in repeated hyper- and/or hypoglycaemic events in patients with Type 1 Diabetes. **Diabetologia** 54:2678-89, 2011 IF₂₀₁₀: 6,973
20. Kauh EA, Mixson LM, Shankar S, McCarthy J, Maridakis V, Morrow L, Heinemann L, Ruddy MK, Herman GA, Kelly DE, Hompesch M Short-term metabolic consequences of prednisone administration in healthy subjects. **Diabetes Obes Metab** 13:1001-1007, 2011 IF₂₀₁₀: 3,415
21. Caduff A, Heinemann L, Talary M, di Benedetto G, Theander S A four hour hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects. **Acta Diabetologica** DOI:10.1007/s00592-011-0292-y, 2011 IF₂₀₁₀: 3,175
22. Weber D, von Hübbenet J, Heckermann S, Faber-Heinemann G, Hess E, Hess G, Kalthener M, Krakow D, Lederle M, Molinski M, Nitzsche G, Reichert D, Reuter H-M, Scheper N, Simonsohn M, Heinemann L Morbiditätsprofile von Diabetes-Patienten: Analyse der ICD-Kodierungen von 105.156 Patienten aus 65 diabetologischen Schwerpunktpraxen. **Diabetes, Stoffwechsel und Herz** 20:357-367, 2011 IF₂₀₁₀: -

Reviews

1. Graf S, Egert S, Heer M Effects of whey protein supplements on metabolism: evidence from human intervention studies. **Curr Opin Clin Nutr Metab Care**, 14(6):569-80, 2011 IF₂₀₁₀: 4,333

2. Stirban A, Tamler R and Veresiu IA Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. **Journal of Men's Health** 8:109-118, 2011 IF₂₀₁₀: 0,390
3. Stirban A Pathogenetische Rolle der Advanced Glycation Endproducts (AGE). **Diabetes, Stoffwechsel, und Herz** 20(3):191-193, 2011 IF₂₀₁₀: -
4. Stirban A The role of polyunsaturated omega-3 fatty acids in cardiovascular protection. **Medic.Ro** 76:50-56, 2011 IF₂₀₁₀: -
5. Stirban A RAAS-Blockade in der Debatte und renale Aspekte des Diabetesmanagements. **Diabetes Congress Report 2**, 2011 IF₂₀₁₀: -
6. Heinemann L, Böcker D Lancing: Quo vadis? **J Diabetes Sci Technol** 5:966-981, IF₂₀₁₀: -
7. Heinemann L, Hompesch M Biosimilar insulins: How similar is similar? **J Diabetes Sci Technol** 5:741-754, 2011 IF₂₀₁₀: -
8. Heinemann L, Benesch C, DeVries JH and the AP@home consortium AP@home: A novel European approach to bring the artificial pancreas home. **J Diabetes Sci Technol** 5:1363-1372, 2011 IF₂₀₁₀: -

Letters and Comments

1. Schneider B, Martin S, Scherbaum WA, Heinemann L, Ludwig V, Kolb H Immortal time bias does not invalidate the association of self-monitoring of blood glucose with better survival of patients with type 2 diabetes in the epidemiological study ROSSO. **Diabetologia** 54:475-476, 2011 IF₂₀₁₀: 6,973
2. Heinemann L Optimizing postprandial metabolic control: Are rapid-acting insulin analogues good enough or do we need ultrafast acting insulins? **Infusystems International** 10(2):9-10, 2011 IF₂₀₁₀: -
3. Heinemann L, Freckmann G Genauigkeit bei der Blutglukosemessung: Was bringt eine Verschärfung der Anforderungen? **Kompodium Diabetes** 6:34-40, 2011 IF₂₀₁₀: -

Book Chapters

1. Heinemann L New ways of insulin delivery. Advanced Technologies & Treatment for Diabetes 2010 Yearbook, edited by Moshe Philip and Tadej Battelino, Wiley-Blackwell, pages 87-133, 2011
2. Heinemann G, Heinemann L Sensoren zum kontinuierlichen Glukosemonitoring in Praxis und Forschung. Kontinuierliches Glukosemonitoring – Klinischer Einsatz und Perspektive, edited by Prof. Dr. Peter Diem, Uni-Med Verlag AG, 1. Auflage - Bremen: UNI-MED, pages 12-44, 2011

Scientific Congress Presentations

Oral Presentations

4th International Conference on Advanced Technologies & Treatments for Diabetes London, UK, February 16-19, 2011

1. Heinemann L New ways of insulin delivery 4th ATTD, ATTD 2011yearbook, in press
2. Heinemann L Biosimilars: How similar is similar? 4th ATTD, ATTD 2011yearbook, in press
3. Heinemann L Degludec: A novel long-acting insulin analogue. 4th ATTD, ATTD 2011yearbook, in press

7. Jahrestagung der Arbeitsgemeinschaft Diabetes-Technologie der DDG Göttingen, Germany, March 18-19, 2011

1. Heinemann L DTM 2010 und ATTD 2011: Was lernen wir davon? 7. AGDT, 2011
2. Heinemann L Single-Port Artificial Pancreas. 7. AGDT, 2011
3. Heinemann L Lancing: What is the future? 7. AGTD, 2011

46. Jahrestagung der Deutschen Diabetes-Gesellschaft Leipzig, Germany, June 01-04, 2011

1. Heinemann L Welche Systeme für das künstliche Pankreas gibt es? Symposium zu Das Künstliche Pankreas – Gewinn für Patienten? 46. DDG, 2011
2. Thomas A, Heinemann L Prognosis of diabetes related complications by continuous glucose monitoring profiles: Data of the JDRF-study analyzed by the Glucose-Pentagon-model. 46. DDG: FV3, **Diabetologie & Stoffwechsel** 6:S5, 2011
3. Heise T, Haahr HL, Jonassen I Insulindegludec – Ein neues ultralang wirksames Basalinsulin mit Multihexamerbildung und geringerer pharmakodynamischer Variabilität als Insulinglargin bei Typ 1 Diabetes (T1D). 46. DDG:FV1, **Diabetologie & Stoffwechsel** 6:S5, 2011

18th IAA Humans in Space Meeting Houston, TX, USA, June 11–16, 2011

1. Frings-Meuthen P, Smith SM and Heer M Salt Intake as an Additional Risk Factor for Bone Loss in Space? 18th IAA, 2011
2. Frings-Meuthen P, Boehmer G, Rittweger J, and Heer M Effects of Potassium Bicarbonate Supplementation on Calcium and Bone. 18th IAA, 2011

29th International Symposium on Diabetes and Nutrition of the Nutrition Study Group of the EASD Rome, Italy, June/July 30–02, 2011

1. Heer M, Smith SM, Frings-Meuthen P, Zwart SR, Baecker N, Biolo G High protein intake improves insulin sensitivity but exacerbates bone resorption in immobility. 29th DNSG, 2011

33rd Congress of Clinical Nutrition and Metabolism of ESPEN, Gothenburg, Sweden, September 03-06, 2011

1. Mazzucco S, Agostini F, Frings-Meuthen P, Svetlic S, De Giorgi S, Mangogna A, Buehlmeier J, Heer M, Biolo G Long-term alkalization decreases protein catabolism and erythrocyte glutathione utilization leading to increased antioxidant capacity during experimental bed rest in humans. 33rd Congress of Clinical Nutrition and Metabolism, 2011

47th Annual Meeting of the European Association for the Study of Diabetes (EASD) Lisbon, Portugal, September 12-16, 2011

1. Bue-Valleskey JM, Schneck KB, Sinha VP, Wondmagegnehu ET, Kapitza C, Miller JW LY2599506, a novel glucokinase activator (GKA) improves fasting and postprandial glucose in patients with type 2 diabetes mellitus. **Diabetologia** 54 (S1):S86 A189, 2011

11th Diabetes Technology Meeting Burlingame, CA, USA, October 27-29, 2011

1. Heinemann L AP@home: Will We Bring the Artificial Pancreas Home? 11th Diabetes Technology Meeting 2011

32nd Annual International Gravitational Physiology Meeting, San Jose, CA, USA November 02-06, 2011

1. Heer M End of the Shuttle Era: Effects of short-term space flight on metabolism and nutrition. Impact on bone metabolism and acid base balance in microgravity and analog studies. 32nd ISGP Meeting, 2011
2. Heer M, Wnendt S, Frings-Meuthen P Fourteen days of light physical workload reverse impaired glucose tolerance induced by bed rest. 32nd ISGP Meeting, 2011
3. Boschmann M, Frings-Meuthen P, Bühlmeier J, Pakula A, Mähler A, Heer M Muscle Metabolism and Acid-Base-Balance during Short-Term Bed Rest. 32nd ISGP Meeting, 2011
4. Frings-Meuthen P, Böhme G, Heer M, Rittweger J Increased serum sclerostin levels during 21-days of head down-tilt bed rest in healthy young test subjects. 32nd ISGP Meeting, 2011

Poster Presentations

46. Jahrestagung der Deutschen Diabetes-Gesellschaft Leipzig, Germany, June 01-04, 2011

1. Schnell O, Hoffmann U, Otter W, Heinemann L, Hunger-Battefeld W, Kulzer B, Klinge A, Ludwig V, Amann-Zalan I, Sturm D, Tschöpe D, Spitzer SG, Stumpf J, Lohmann T, Dörr R Die „Silent Diabetes“ Studie: Orale Glukosetoleranztest vs. HbA1c zur Neudiagnose des Diabetes bei Patienten mit KHK-Verdacht. 46. DDG: P132, **Diabetologie & Stoffwechsel** 6:S49, 2011
2. Friedrich C, Gräfe-Mody U, Port A, Ring A, Heise T, Halabi A, Wörle HJ Pharmakokinetik des DPP-4 Inhibitors Linagliptin bei chronischer Niereninsuffizienz. 46. DDG: P215, **Diabetologie & Stoffwechsel** 6:S77, 2011

3. Weber D, Kalthener M, Scheper C, Hübner J von, Heckermann S, Reichert D, Hess G, Hess E, Molinski M, Krakow D, Reuter HM, Nitzsche G, Simonsohn M, Lederle M, Faber-Heinemann G, Heinemann L Evaluierung der Morbiditäten und Co-Morbiditäten von Patienten mit Diabetes die in diabetologischen Schwerpunkt-Praxen behandelt werden. 46. DDG: P230, **Diabetologie & Stoffwechsel** 6:S81, 2011

American Diabetes Association´s 71th Scientific Sessions San Diego, CA, June 24-28, 2011

1. Troyer MD, Hompesch M, Jax T, Pramanik B, Liu F, Morrow L, Win K, Reynders T, Liu C, Engel S, Heise T, Maliwat E, Denney W, Kelley DE, Wagner JA, Stoch Recovery from hypoglycemic clamp in type 2 diabetes (T2DM) patients during beta-adrenergic blockade plus glucagon receptor blockade with MK-0893. **Diabetes** 60 (S1):495-P, 2011
2. Bue-Valleskey J, Schneck K, Sinha VP, Wondmagegnehu E, Kapitza C, Miller JW LY2599506, a novel glucokinase activator (GKA), improves fasting and postprandial glucose in patients with type 2 diabetes mellitus (T2DM). **Diabetes** 60 (S1):993-P, 2011
3. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. **Diabetes** 60 (S1):960-P, 2011
4. Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. **Diabetes** 60 (S1):49-LB, 2011
5. Heise T, Hövelmann U, Nosek L, Feldmann A, Rasmussen S, Haahr H Insulin degludec has a two-fold longer half life and a more consistent pharmacokinetic profile than insulin glargine. **Diabetes** 60 (S1):37-LB, 2011
6. Kurtzhals P, Heise T, Strauss HM, Bottcher SG, Granhall C, Haahr H, Jonassen IB Multi-hexamer formation is the underlying mechanism behind the long-acting glucose-lowering effect of insulin degludec. **Diabetes** 60 (S1):42-LB, 2011
7. Breton M, Heinemann L, Keith S, Pettis RJ, Kovatchev B Comparison between intradermal and subcutaneous insulin delivery via a novel biphasic model of insulin absorption. **Diabetes** 59 (S1):525-P, 2010

29th International Symposium on Diabetes and Nutrition of the Nutrition Study Group of the EASD Rome, Italy, June/July 30-02, 2011

1. Heer M, Wnendt S, Frings-Meuthen P Fourteen days of light physical workload reverse impaired glucose tolerance induced by bedrest. 29th DNSG, 2011

47th Annual Meeting of the European Association for the Study of Diabetes (EASD) Lisbon, Portugal, October 12-16, 2011

1. Polidori D, Sha S, Ghosh A, Farrell K, Rothenberg P, Heise T Determining the renal threshold for glucose excretion: validation of a new method. **Diabetologia** 54 (S1):S225 A546, 2011
2. Heise T, Hövelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine Multi-hexamer formation as the underlying basis for the ultra-long glucose-lowering effect of insulin degludec **Diabetologia** 54 (S1):S425 A1046, 2011

3. Kurtzhals P, Heise T, Strauss HM, Bottcher SG, Granhall C, Haahr H, Jonassen I Multi-hexamer formation as the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. **Diabetologia** 54 (S1):S426 A1049, 2011
4. Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H Ultra-long acting insulin degludec has a flat and stable glucose-lowering effect. **Diabetologia** 54 (S1):S429 A1055, 2011
5. Jax T, Kapitza C, Nilsson S, Breuer, O The effect of KB003305, a liver-selective glucocorticoid receptor antagonist, on fasting plasma glucose and oral glucose tolerance after multiple oral doses in patients with diabetes type 2. **Diabetologia** 54 (S1):S364 A892, 2011
6. Hövelmann U, Hermanski L, Nosek L, Kapitza C, Heise T, Heinemann L, Jax T Systematic evaluation of the influence of hyperglycaemia on diastolic myocardial function. **Diabetologia** 54 (S1):S503 A1248, 2011
7. Heer M, Wnendt S, Frings-Meuthen P Bed rest as a model for immobility-induced insulin resistance. **Diabetologia** 54 (S1):S231 A558, 2011

14th Annual CDA/CSEM Professional Conference and Annual Meeting Toronto, ON, Canada October 26-29, 2011

1. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Heinemann L, Haahr H The pharmacodynamic variability of Insulin Degludec is consistently lower than insulin glargine over 24 hours at steady state. **Can J Diabetes** 35:394-395, 2011

11th Diabetes Technology Meeting Burlingame, CA, USA, October 27-29, 2011

1. Guerra S, Facchinetti A, Sparacino G, Bruttomesso D, Avogaro A, DeVries JH, Luijf YM, Ellmerer M, Mader JK, Heinemann L, Benesch C, Cobelli C, on behalf of the AP@home Consortium Accuracy of continuous glucose monitoring enhanced online via a deconvolution-based algorithm. 11th DTM: A58, 2011
2. Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Ellmerer M, Heinemann L, Mader JK, DeVries JD, on behalf of the AP@home consortium, Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. 11th DTM: A95, 2011

21th World Diabetes Congress International Diabetes Federation, Dubai, United Arab Emirates, December 03-08, 2011

1. Heise T, Hövelmann U, Nosek L, Böttcher SG, Granhall C, Haahr H Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile compared to insulin glargine. 21th IDF:P1444, 2011
2. Nosek L, Heise T, Böttcher SG, Hastrup H, Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. 21th IDF:P1452, 2011
3. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H Ultra-long-acting insulin degludec has consistently lower pharmacodynamic variability than insulin glargine over 24 h at steady state. 21th IDF:P1453, 2011

Advanced Training Courses

Science Sessions

1. 19. Januar 2011
ClampArt – Technik, die begeistert
Dr. Judith Haensler
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
2. 09. Februar 2011
Direkte Messung sympathischer Aktivität beim Menschen mittels Mikroneurografie
PD Dr. Jens Tank & Karsten Heusser
Zentrum für Pharmakologie und Toxikologie – Institut für Klinische Pharmakologie,
Medizinische Hochschule Hannover, Germany
3. 16. Februar 2011
Autonomes Nervensystem und Energiestoffwechsel
Dr. Leona Plum
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
4. 9. März 2011
Glukosestoffwechsel und Lebenserwartung
Prof. Dr. Michael Ristow
Institut für Ernährungswissenschaften, Inhaber des Lehrstuhls für Humanernährung der
Universität Jena, Germany
5. 20. April 2011
Ausdauer *versus* Krafttraining bei Typ 2 Diabetikern
Prof. Klaus Baum
Deutsche Sporthochschule Köln, Leiter des Trainingsinstituts Prof. Baum GmbH Köln, Germany
6. 04. Mai 2011
Kognition bei intensivierter Insulintherapie
Prof. Dr. Karin Weissenborn
Klinik für Neurologie, Medizinische Hochschule Hannover, Germany
7. 08. Juni 2011
Kardiovaskuläres Risiko und Diabetes Mellitus Typ 2
Prof. Dr. Nikolaus Marx
Klinik für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin am Klinikum
der RWTH Aachen, Germany
8. 20. Juli 2011
Freie Fettsäuren, Insulinsekretion und Insulinsensitivität
Dr. Burak Salgin
Klinik für Allgemeine Pädiatrie, Heinrich-Heine-Universität Düsseldorf, Germany
9. 28. September 2011
Wy men's hearts break – a story of hypogonadism, insulin resistance and endothelial
dysfunction

Prof. Dr. Ronald Tamler

Clinical Director, Mount Sinai School of Medicine New York, USA

10. 23. November 2011
Paläokardiologie – von Steinzeitjägern und Dinosauriern
Dr. Gunnar Plehn
Klinik für Kardiologie und Angiologie, Marienhospital Herne, Klinikum der Ruhr-Universität Bochum, Germany
11. 07. Dezember 2011
Standardized nutrition and metabolic multi-platform phenotyping in healthy volunteers
PD Dr. Thomas Skurk
Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Technische Universität München, Germany

Trainings with External Participants

1. **Methoden in der experimentellen Ernährungsforschung**
03. – 07. Januar 2011
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
Masterstudiengang Humanernährung Rheinische Friedrich-Wilhelms-Universität Bonn,
Germany
2. **DuET 2011 Düsseldorf Education on Trials**
05. – 06. Oktober 2011
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
Novo Nordisk, Region Europe A/S
3. **Profil – Glucose-Clamp-Technique Introduction Course**
30. November 2011
Anders Jespersen, Charlotte Thim Hansen, Jeppe Zacho
Profil Institut für Stoffwechselforschung GmbH Neuss, Germany
Novo Nordisk Bagsvaerd, Denmark

Scientific Communication

Newspaper Articles

1. PZ Pharmazeutische Zeitung online
Ausgabe 39/2011
Dr. med. Tim Heise
Diabetes – Das Ultra-Langzeitinsulin
2. Galeria Vital online
10. November 2011
Dr. med. Alin Stirban
Experteninterview Expertentelefon “Polyneuropathie“
3. Stern
Ausgabe 23/2011
www.stern.de/diabetesforschung
Profil Institut für Stoffwechselforschung GmbH / Prof. Dr. Peter Sawicki
Patienten sind kompetent

Granted Research Projects

1. **AP@Home – Bringing the Artificial Pancreas Home**
EU Project 7th Framework Programme (further information: <http://www.apathome.eu/>)
2. **Clinical Application for Metabolic Profiling (EU-CLAMP)**
EU Project 7th Framework Programme (further information: <http://www.euclamp.eu/>)
3. **Virtual Liver Network**
BMBF Project (further information: <http://www.virtual-liver.de/>)
4. **Untersuchung zum Knochenstoffwechsel** anhand von ISS Experimenten, ESA Bed Rest Experimenten, und MARS500 Experimenten, Rheinische Friedrich-Wilhelms-Universität Bonn, BMWi, Projektträger Raumfahrt
5. **Untersuchungen zur Auswirkung der Nährstoffzusammensetzung/-Supplementation auf den Knochen- und Kohlenhydratstoffwechsel anhand folgender Einzel-Projekte**, Toulouse-MTBR-Bettruhe-Experimente PROPEI und Bone Quality, Antarktisstation Concordia Projekt MONU, ISS-Experiment Pro K, Rheinische Friedrich-Wilhelms-Universität Bonn, BMWi, Projektträger Raumfahrt

Awards & Appointments

1. **Lutz Heinemann**
Appointed as Managing Editor of the Journal of Diabetes Science and Technology
2. **Martina Heer**
Appointed as Member of the Editorial Board of the Journals
- Journal of Extreme Physiology & Medicine
- Scientific World Journal
3. **Martina Heer**
Appointed as President of the International Society for Gravitational Physiology